HMNC Brain Health to Participate in the Psychedelic Science Conference 2023 and the H.C. Wainwright & Co. 4th Annual Neuropsychiatry Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) — HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company, pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that the Company will participate in the following conferences in June.

Psychedelic Science Conference 2023

HMNC to participate in the Psychedelic Science Conference 2023, at the Colorado Convention Center in Denver, Colorado from June 21-23, 2023. Dr. Daniel Gehrlach, HMNC’s Associate Director – Biomarkers, will take part in the panel ‘AI and Computational Approaches to Drug Discovery’, at 12:00pm MDT on June 22, 2023 in the Mile High 3 room. To register for the conference please click here.

H.C. Wainwright & Co. 4th Annual Neuropsychiatry Virtual Conference

HMNC to present virtually at the H.C. Wainwright & Co. 4th Annual Neuropsychiatry Virtual Conference on Monday, June 26, 2023. In addition, HMNC’s management team will participate in one-on-one investor meetings over the duration of the conference. To register for the conference, please follow this link.

To schedule a meeting with HMNC’s management team throughout the conferences, please contact KCSA Strategic Communications at hmncbrain@kcsa.com.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a global precision psychiatry biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, leading to higher remission rates. The company develops a unique pipeline for targeting both Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The Company has a presence in Germany and the US and is backed by a renowned global VC, several family offices and a strategic healthcare investor. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

Media Contact (U.S.):
Anne Donohoe
+1 212-896-1265
hmncbrain@kcsa.com  

Investor Contact (U.S.):
Sophia Bashford
+1 929-246-7307
hmncbrain@kcsa.com

Staff

Recent Posts

Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025

Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease…

3 hours ago

Best Supplements For Muscle Growth: Top Legal Bodybuilding Supplements & Anabolic Steroids For Bulking, Cutting & Strength

Backed by Wolfson Brands (UK) Limited, Discover the best supplements for muscle growth, including top…

19 hours ago

Mitolyn Reviews 2025: Exploring Faux Reviews, Consumer Complaints, & How to Buy Real Mitolyn Purple Peel Exploit!

Mitolyn Mitolyn Seattle, May 03, 2025 (GLOBE NEWSWIRE) -- As more individuals become health-conscious, and…

19 hours ago

Buy Ibutamoren MK 677 SARMS for Sale Online: MK-677 Before After Results – Where to Order Legal Ibutamoren SARM OTC, Buyers Guide from CrazyBulk

CrazyBulk CrazyBulk New York City, May 03, 2025 (GLOBE NEWSWIRE) -- If you’re serious about…

19 hours ago

Bioma Review 2025: Revolutionizing Gut Health or Just Another Fad? Honest Analysis Inside By Bioma Probiotic!

Gut transformation through Bioma a perfectly blended combination of probiotics prebiotics and postbiotics Bioma Bioma…

19 hours ago

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR…

19 hours ago